CRISPR Tx Taps Former rEVO, Genzyme Exec As New CFO

Xconomy Boston — 

Basel, Switzerland and Cambrige, MA-based CRISPR Therapeutics has named Marc Becker its chief financial officer. Becker is coming off a stint as senior vice president and CFO of rEVO  Biologics—where he helped prep the company for its 2014 IPO—and was a finance executive at Genzyme before that. CRISPR Therapeutics is one of three companies with operations in the Boston area, along with Editas Medicine (NASDAQ: EDIT) and Intellia Therapeutics, that are developing therapeutics based on the CRISPR-Cas9 gene editing system. Editas is the only one of the three to go public as of yet.